* Genta Inc., of San Diego, said the eighth non-Hodgkin's lymphomapatient treated in a Phase I/II trial with G3139 achieved a completeresponse (disappearance of all disease). Also, four of eight patientsdemonstrated clinical and/or biological activity. Separately, Gentasaid the National Cancer Institute will fund and conduct studies of theantisense drug in various tumors.
* Gilead Sciences Inc., of Foster City, Calif., said it discoveredantisense oligonucleotides that provide potent and selective inhibitionof targeted genes in vitro using compounds one-third the size of first-generation technologies. The data were presented in the July 1, 1996,Nature Biology.
* Immunomedics Inc., of Morris Plains, N.J., completed constructionand began validation of a 7,500-square-foot facility at its MorrisPlains headquarters.
* Interferon Sciences Inc., of New Brunswick, N.J., said its licenseein Mexico began a trial of the injectable formulation of Alfa-n3,Interferon's natural source interferon, for hepatitis C.
* Neocrin Co., of Irvine, Calif., obtained exclusive rights to a patenton diabetes cell therapy from the University of Texas. The licenserelates to the encapsulation of biological materials usingphotopolymerization of water soluble molecules.
* OraVax Inc., of Cambridge, Mass., said underwriters of its recentpublic offering exercised overallotment options on 300,000 shares at$7.25 each, bringing gross proceeds to nearly $16.7 million. (SeeBioWorld Today, June 27, 1996, p. 2.)
* Theratechnologies Inc., of Montreal, filed to distribute 4.25 millionClass B subordinate voting shares at $3 each, of which 2.5 millionare new shares and 1.75 million are being sold in a secondaryoffering. The estimated net proceeds will be C$6.75 million.
(c) 1997 American Health Consultants. All rights reserved.